ESMO 2022 | The inclusion of patients with brain metastases in clinical trials

Angelika Starzer, MD, Medical University of Vienna, Vienna, Austria, discusses the significance of including patients with brain metastases in clinical trials. Historically, patients have been excluded from trials, however, real-world data has demonstrated an abundance of patients with various cancers develop brain metastases, highlighting the importance of including this patient population. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.